You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 6653 results
  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy

    SBC: AFFIRMED PHARMA, LLC            Topic: NEI

    Abstract Radiation induced keratopathy results in significant ocular surface disease, stem cell deficiency, vision loss, discomfort, and subsequent poor quality of life, affecting up to 23% of patients receiving radiation therapy for head and neck malignancies [1]. Studies have pointed out functional roles of corneal neurons and secretory cells of the lacrimal gland in the etiology of radiation in ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Targeted ColQ gene therapy for Congenital Myasthenic Syndromes

    SBC: Amplo Biotechnology, Inc.            Topic: 106

    PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection

    SBC: Nutriforward, LLC            Topic: 100

    Project Summary Choroidal neovascularization (CNV) occurs in both age-related macular degeneration (AMD) and diabetic retinopathy (DR). While anti-VEGF treatment has improved the visual outcome considerably, they are far from achieving a 100% success rate (non-responsiveness between 8 and 50%). Inherited retinal degenerations (IRDs) are a group of heterogeneous, progressive, visually debilitating ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder

    SBC: PHOENIX PHARMALABS, INC.            Topic: NIDA

    Abstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Inducible HMGB1 antagonist for viral-induced acute lung injury.

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NHLBI

    For more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a portable beat-to-beat fetal ECG system

    SBC: AUSCULTECH DX LLC            Topic: NICHD

    Project Summary There are 24,000 stillbirths per year in the United States, and 2.6 million stillbirths per year worldwide, with no significant decrease in the last decade. Abnormal fetal heart rhythms, such as long QT syndrome, are thought to play an important role in these deaths, and may cause 3- 10% of unexplained stillbirths. This is in addition to known fetal arrhythmias, which affect 1-3% o ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer

    SBC: WNTRIX INC            Topic: 102

    PROJECT SUMMARY Colorectal cancer is still a major cause of cancer-related death in the world and only a small subset of patients benefits from therapy by immune checkpoint inhibitors. Antibody–drug conjugates (ADCs) are monoclonal antibodies (mAbs) that are covalently linked to cell-killing drugs and have emerged as a major modality in anti-cancer treatment. This approach combines high specific ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Developing RNA therapeutics for rare neurodevelopmental disorders

    SBC: Dayi Therapeutics, Inc.            Topic: NICHD

    PROJECT SUMMARY Developing RNA therapeutics for rare neurodevelopmental disorders Monogenic diseases caused by mutations in single genes are individually rare, but collectively common affecting 10% of the world population. Many of these diseases are disabling or even life threatening with no available treatment. The underlying molecular mechanisms vary. Both loss of gene function and gain of toxic ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD

    SBC: Aviara Pharmaceuticals, Inc.            Topic: 300

    Inflammatory bowel disease (IBD) is comprised mainly of Crohn’s Disease (CD) and Ulcerative Colitis (UC), and is characterized by a chronic non-resolving inflammatory response in the intestinal mucosa. Although the exact etiology is unknown, dysbiosis, genetic, environmental, and immunologic factors are all thought to play roles in this multifactorial disease. There are no cures, and in most cas ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government